Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 9, 2025
Daily News
December 9, 2025
- FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
- Erbitux-Braftovi Combo Now Available for Frontline BRAF-Mutant Colorectal Cancer in Japan
December 9, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…